Published:Journal of Chromatographic Science,
ISSN 0021-9665Volume
41, Number 1, January 2003, pp. 17-21
Development and Validation of a High-Performance Liquid Chromatography–Electrospray
Ionization– Mass Spectrometry Assay for the Determination of Zaleplon
in Human Plasma
Fang Feng, Juanjuan Jiang, Hui Dai, and Jie Wu
Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing
China , 210009
In this paper, a sensitive and rapid chromatographic procedure
using a selective analytical detection method (electrospray ionization–mass
spectrometry in selected-ion monitoring mode) in combination with a simple
and efficient sample preparation step is first presented for the determination
of zaleplon in human plasma. The separation of the analyte, internal standard,
and possible endogenous compounds are accomplished on a phenomenex Luna 5-µm
C8(2) column (250- ¥ 4.6-mm i.d.) with methanol–water (75:25, v/v)
as the mobile phase. In order to optimize the mass detection of zaleplon, several
parameters such as ionization mode, fragmentor voltage, m/z ratios of ions
monitored, type of organic modifier, and eluent additive in the mobile phase
are discussed. An internal standard is selected to guarantee the quantitative
accuracy. Each analysis takes less than 6 min. The calibration curve of zaleplon
in the range of 0.1–60.0 ng/mL in plasma is linear with a correlation
coefficient of > 0.9992, and the detection limit (s/n = 3) is 0.1 ng/mL.
The within- and between-day variations (relative standard deviation) in the
zaleplon plasma analysis are less than 2.4% (n = 15) and 4.7% (n = 15), respectively.
The application of this method is demonstrated for the analysis of zeleplon
plasma samples in a Phase-I human pharmacokinetic study.
Reproduction
of editorial content of this journal is prohibited without publishers
permission.
This
article is available in its entirety by fax for $40.00.
Visa, MasterCard & Amex accepted.
To
order electronicallyclick here or call: 847-647-2900 ext. 1323 or fax request to: 847-647-1155.